Proliferative vitreoretinopathy: Immunoreactive endothelin-1

Annals of Ophthalmology

Volumn 36, Issue 1, 2004, Pages 24-28

  Roldán Pallarés, Manuela ^a   Rollín, Raquel ^b   Bernal, Rosa ^b   Ripodas, Ainhoa ^b   Marañón, José Angel ^b   Fernández Cruz, Arturo ^b   Fernández Durango, Raquel ^c  

^a Department of Ophthalmology ^*  (Spain)

^b Research Unit   (Spain)

^c UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOTHELIN 1; IMMUNOREACTIVE ENDOTHELIN 1; NEUROPEPTIDE; UNCLASSIFIED DRUG; VASOCONSTRICTOR AGENT;

ADULT; AGED; ARTICLE; BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; IMMUNOREACTIVITY; MALE; PEPTIDE SYNTHESIS; PROTEIN CONTENT; RETINA DETACHMENT; SUBRETINAL FLUID; VITREORETINOPATHY;

EID: 18344410670     PISSN: 15304086     EISSN: None     Source Type: Journal    
DOI: 10.1385/AO:36:1:24     Document Type: Article

References (28)

1. Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, Yazaki Y, Goto K, Masaki T. A novel potent vasoconstrictor peptide produced by endothelial cells. Nature (London). 1988; 332:411-5.
2. Battistini B, Chailler P, D'Orleans-Juste P, Brière N, Sirois P. Growth regulatory properties of endothelins. Peptides. 1993;14: 385-9.
3. Arai H, Hori S, Aramori I, Ohkubo H, Nakanishi S. Cloning and expression of cDNA encoding and endothelin receptor. Nature (London). 1990;348:730-2.
4. Sakurai T, Yanagisawa M, Takuwa Y, et al. Cloning of CDNA encoding a non isopeptide selective subtype of endothelin receptor. Nature (London). 1990;348:732-5.
5. Sakurai T, Yanagisawa M, Masaki T. Molecular characterisation of endothelin receptor. Trends Pharmacol Sci. 1992;13:103-8.
6. Warner TD, Mitchell JA, De Nucci G, Vane JR. Endothelin-1 and endothelin-3 release EDRF from isolated perfused arterial vessels of the rat and rabbit. J Cardiovas Pharmacol. 1989;13:S85-S88.
7. Inoue A, Yanagisawa M, Kimura S, et al. The human endothelin family: three structurally and pharmacologically distinct isopeptides predicted by three separate genes. Proc Natl Acad Sci USA. 1989;86:2863-7.
8. MacKumber MW, Jampel HD, Snyder SH. Ocular effect of endothelin. Arch Ophthalmol. 1991;109:705-9.
9. Chakravarthy U, Douglas AJ, Bailie JR, McKibben B, Archer DB. Immunoreactive endothelin distribution in ocular tissues. Invest Ophthalmol Vis Sci. 1994;35:2448-54.
10. Ripodas A, de Juan JA, Roldám Pallarés M, et al. Localisation of Endothelin-1 mRNA expression and immunoreactivity in the retina and optic nerve from human and procine eye. Evidence for endothelin-1 expression in astrocytes. Brain Res. 2001;912:137-143.
11. Rachal WF, Burton TC. Changing concepts of failures after retinal detachment surgery. Arch Ophthalmol. 1979;97:480-3.
12. The Retinal Society Terminology Commitee. The classification of retinal detachment with proliferative vitreoretinopathy. Ophthalmology. 1983;90:121-5.
13. Ryan SJ. The pathophysiology of proliferative vitreoretinopathy and its management. Am J Ophthalmol. 1985;100:188-93.
14. Smith-Thomas L, Haycock JW, Metcalfe R. Involvement of calcium in retinal pigment epithelial cell proliferation and pigmentation. Curr Eye Res. 1998;8:813-22.
15. Lincoff H, Baras I, McLean JM. Modifications to the Custodis procedure for retinal detachment. Arch Ophthalmol. 1965;73:160-3.
16. Machemer R, Aaberg TM, Freeman HM, Irvine AR, Lean JS, Michels RM. An updated classification of retinal detachment with proliferative vitreoretinopathy. Am J Ophthalmol. 1991;112:159-165.
17. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the folin phenol reagent. J Biol Chem. 1951;193: 265-275.
18. Huerva V, Sinues B, Canto LM, Lanuza J, Palomar A. Apoprotein B in subretinal fluid. Int Ophthalmol. 1996-97;20:181-5.
19. B) in rat retina. J Neurochem. 1993;61:1113-9.
20. Limb GA, Little BC, Meager A. Cytokines in proliferative vitreoretinopathy. Eye. 1991;5:686-693.
21. Kauffmann DJ, Van Meurs JC, Mertens DA, Peperkamp E, Master C, Gerritsen ME. Cytokines in vitreous humor: Interleukin-6 is elevated in proliferative vitreoretinopathy. Invest Ophthalmol Vis Sci. 1994;35:900-6.
22. Kosnosky W, Li TH, Pakalnis VA, Fox A, Hunt RC. Interleukin-1 beta changes the expression of metalloproteinases in the vitreous humor and induces membrane formation in eyes containing pre-existing retinal holes. Invest Ophthalmol Vis Sci. 1994;35:4260-7.
23. Schweigerer L, Malerstein B, Neufeld G, Gospodarowicz D. Basic fibroblast growth factor is synthesized in cultured retinal pigment epithelial cells. Biochem Biophys Res Commun. 1987;143:934-40.
24. Baudouin C, Fredj-Reygrobellet D, Brignole F, Negre F, Lapalus P. Growth factors in vitreous and subretinal fluid cells from patients with proliferative vitreoretinopathy. Ophthalmic Res. 1993;25:52-9.
25. Grisanti S, Wiedermann P, Heimann K. Die proliferative vitreoretinopathie. Zur bedeutung des proteintransfers durch die blut-retina-schranke. Ophtalmologie. 1993;90:468-71.
26. Grisanti S, Guidry C, Heimann K. Contraction of extracellular matrix by transdifferentiated retinal pigment epithelial cells, inducers and inhibitors. Ophthalmologe. 1996;93:709-13.
27. Matsura A, Kawashima S, Yamochi W, et al. Vascular endothelial growth factor increases endothelin-converting enzyme expression in vascular endothelial cells. Biochem Biophys Res Commun. 1997; 235:713-6.
28. Connor TB Jr, Roberts AB, Sporn MB, et al. Correlation of fibrosis and transforming growth factor-beta type 2 levels in the eye. J Clin Invest. 1989;83:1661-6.